糖原贮积病Ib型患者的基因变异与临床特征
该回顾性队列研究纳入上海单中心2000年11月1日至2024年6月30日诊治的113例中国GSDIb患者(儿童96例[85%],男性67例[59%]),基因诊断中位年龄1.4岁(范围0.0-35.5),鉴定出38个新发SLC37A4变异。≤2岁以低血糖和代谢紊乱为主(45%),2.1-5.0岁身材矮小(75%)、感染(75%)和反复鼻出血(31%)更常见,呼吸道感染频率在中位7.0岁(IQR 3.5-10.5)后下降。44例(46%)在中位6.0岁(IQR 3.0-12.0)发生IBD,其中14%在中位10.5岁(IQR 5.8-19.6)发生IBD相关关节炎;末次随访实际身高与目标身高z评分差值(Δ身高z评分)均值(SD)-2.11(1.76),即使经生玉米淀粉治疗也未显著增加;合并IBD者Δ身高z评分-2.99(1.70)显著低于无IBD者-1.36(1.44)(P<.001)。10例(9%)死于GSDIb并发症,包括代谢紊乱、脓毒症和/或重症肺炎(n=8)、IBD(n=1)和肺动脉高压(n=1)。
要点
- 113例中国GSDIb患者基因诊断中位年龄1.4岁(范围0.0-35.5),鉴定出38个新发SLC37A4变异。
- 44例(46%)发生IBD,中位年龄6.0岁(IQR 3.0-12.0);其中14%发生IBD相关关节炎,中位年龄10.5岁(IQR 5.8-19.6)。
- 合并IBD者Δ身高z评分-2.99(1.70)显著低于无IBD者-1.36(1.44)(P<.001);总体Δ身高z评分-2.11(1.76),生玉米淀粉治疗后未显著增加。
- 10例(9%)死于GSDIb并发症:代谢紊乱、脓毒症和/或重症肺炎(n=8)、IBD(n=1)、肺动脉高压(n=1)。
- ≤2岁以低血糖和代谢紊乱为主(45%);2.1-5.0岁身材矮小(75%)、感染(75%)、反复鼻出血(31%)更常见;呼吸道感染频率在中位7.0岁(IQR 3.5-10.5)后下降。
适用人群与场景
- 上海单中心2000年11月1日至2024年6月30日诊治的113例中国GSDIb患者,其中儿童96例(85%),男性67例(59%)。
处置流程与药物剂量
- 生玉米淀粉治疗:原文提及患者接受生玉米淀粉治疗,但未给出剂量、频次或目标值。
红旗征与不能漏的情况
- 代谢紊乱、脓毒症和/或重症肺炎是GSDIb患者死亡的主要原因(n=8),需警惕。
- IBD(n=1)和肺动脉高压(n=1)亦可导致死亡。
研究设计与关键结果
- 研究类型:回顾性队列研究;样本量113例;单中心(上海);人群为中国GSDIb患者。
- 主要终点:描述基因和临床特征;鉴定出38个新发SLC37A4变异;基因诊断中位年龄1.4岁(范围0.0-35.5)。
- 临床特征:≤2岁低血糖和代谢紊乱为主(45%);2.1-5.0岁身材矮小(75%)、感染(75%)、反复鼻出血(31%)更常见;呼吸道感染频率在中位7.0岁(IQR 3.5-10.5)后下降。
- IBD:44例(46%)发生IBD,中位年龄6.0岁(IQR 3.0-12.0);其中14%发生IBD相关关节炎,中位年龄10.5岁(IQR 5.8-19.6)。
- 生长:末次随访Δ身高z评分均值(SD)-2.11(1.76),生玉米淀粉治疗后未显著增加;合并IBD者-2.99(1.70)显著低于无IBD者-1.36(1.44)(P<.001)。
- 死亡:10例(9%)死于GSDIb并发症,包括代谢紊乱、脓毒症和/或重症肺炎(n=8)、IBD(n=1)、肺动脉高压(n=1)。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,本研究拓宽了GSDIb的基因和临床谱,提示GSDIb与肠道、生长和生存结局之间存在关联。
- 作者指出,迄今尚无先前研究报告IBD相关关节炎。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Glycogen storage disease type Ib (GSDIb) is a rare metabolic disorder characterized by impaired glucose-6-phosphate transporter function with limited descriptions.
OBJECTIVE: To describe the genetic and clinical features of Chinese patients with GSDIb.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study retrieved the medical records of 113 Chinese patients with GSDIb treated at a single institution in Shanghai from November 1, 2000, to June 30, 2024.
MAIN OUTCOMES AND MEASURES: Biochemical parameters and clinical features (infections, inflammatory bowel disease [IBD], kidney and cardiovascular issues, growth and puberty) at baseline and the last follow-up, all-cause mortality, and mental and social development were assessed.
RESULTS: A total of 113 patients (96 children [85%]; 67 males [59%]) had GSDIb genetically diagnosed at a median age of 1.4 (range, 0.0-35.5) years. Thirty-eight novel SLC37A4 variants were identified. Hypoglycemia and metabolic derangements were the primary concerns in patients aged 2 years or younger (45%). Short stature (75%), infections (75%), and recurrent epistaxis (31%) became more prevalent in patients aged 2.1 to 5.0 years. The frequency of respiratory tract infection decreased after a median age of 7.0 (IQR, 3.5-10.5) years. Forty-four patients (46%) developed IBD at a median age of 6.0 (IQR, 3.0-12.0) years, 14% of whom developed IBD-associated arthritis at a median age of 10.5 (IQR, 5.8-19.6) years. The mean (SD) difference between the z scores of actual height and target height (Δ height z scores) at the final visit (-2.11 [1.76]) did not significantly increase even after uncooked cornstarch treatment. The mean (SD) Δ height z scores of the patients with IBD (-2.99 [1.70]) were significantly lower than those without IBD (mean [SD], -1.36 [1.44]) (P < .001). Ten patients (9%) died due to complications of GSDIb, including metabolic derangements, sepsis, and/or severe pneumonia (n = 8), IBD (n = 1), and pulmonary hypertension (n = 1).
CONCLUSIONS AND RELEVANCE: In this cohort study, the genetic and clinical spectra of GSDIb were broadened, suggesting associations between GSDIb and bowel, growth, and survival outcomes. To date, no previous study reported IBD-associated arthritis.
参考来源
- Xia Y, Sun Y, Du T, et al. Genetic Variants and Clinical Features of Patients With Glycogen Storage Disease Type Ib. JAMA Netw Open. 2025. PMID: 40009380. doi:10.1001/jamanetworkopen.2024.61888
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。